Protagonist Therapeutics (PTGX) Cash from Financing Activities (2015 - 2026)

Protagonist Therapeutics has reported Cash from Financing Activities for 12 years, with the latest figure at $23.4 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 104.26% year-over-year to $23.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.8 million (up 15.61% YoY) and the FY2025 annual result came in at $22.9 million, down 11.56% from the prior year.
• Cash from Financing Activities advanced to $23.4 million in Q1 2026 per PTGX's latest filing, from $2.8 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $108.2 million in Q2 2023 and troughed at $527000.0 in Q4 2023.
• A 5-year average of $15.4 million and a median of $5.7 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities tumbled 99.46% in 2022, then jumped 15807.65% in 2023.
• Over 5 years, Cash from Financing Activities stood at $553000.0 in 2022, then fell by 4.7% to $527000.0 in 2023, then soared by 664.9% to $4.0 million in 2024, then decreased by 29.62% to $2.8 million in 2025, then surged by 723.9% to $23.4 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $23.4 million, $2.8 million, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.